Core Points - Heng Rui Pharmaceutical (01276) announced the actual unlocking of shares under its 2022 employee stock ownership plan, totaling 2.8303 million shares, which accounts for 0.04% of the company's current total share capital [1] - As of November 14, 2025, 1.6568 million shares will be transferred non-traditionally to the holders of the employee stock ownership plan, while 1.1735 million shares will be sold through centralized bidding [1] - The management committee of the 2022 employee stock ownership plan will carry out the corresponding asset distribution work based on the relevant agreements of this employee stock ownership plan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 中國上海 2025年11月14日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-178 江苏恒瑞医药股份有限公司 关于 2022 年员工持股计划第三个锁定期解锁 执行完毕的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of November 14, with Northeast Electric (00042) leading at 831.03% and Ningde Times (03750) at -9.94% [1][2] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042) with a premium of 831.03% - Sinopec Oilfield Service (01033) with a premium of 279.27% - Hongye Futures (03678) with a premium of 276.70% [1][2] - The bottom three stocks with the lowest AH premium rates are: - Ningde Times (03750) with a premium of -9.94% - China Merchants Bank (03968) with a premium of -0.10% - Heng Rui Pharmaceutical (01276) with a premium of 5.22% [1][2] Deviation Values - The stocks with the highest deviation values are: - Sinopec Oilfield Service (01033) with a deviation of 36.09% - Hongye Futures (03678) with a deviation of 32.04% - Zhejiang Shibao (01057) with a deviation of 29.03% [1][2] - The stocks with the lowest deviation values are: - Andeli Juice (02218) with a deviation of -18.61% - Ganfeng Lithium (01772) with a deviation of -17.09% - China Life (02628) with a deviation of -16.43% [1][2][3]

Performance Highlights - Tencent Holdings (00700.HK) reported Q3 revenue of 192.87 billion yuan, a year-on-year increase of 15% and a quarter-on-quarter increase of 5%. Net profit reached 63.13 billion yuan, up 19% year-on-year and 13% quarter-on-quarter [2] - Semiconductor Manufacturing International Corporation (00981.HK) achieved Q3 sales revenue of 2.38 billion USD, a quarter-on-quarter increase of 7.8% and a year-on-year increase of 9.7%. Gross margin improved to 22.0%, up 1.6 percentage points quarter-on-quarter [3] - JD Group (09618.HK) reported Q3 total revenue of 299.06 billion yuan, a year-on-year increase of 14.85%, while net profit decreased by 55.03% to 5.28 billion yuan [4] - JD Logistics (02618.HK) recorded Q3 revenue of 55.08 billion yuan, a year-on-year increase of 24.1%, with operating profit rising by 125.3% to 1.24 billion yuan [5] - Bilibili (09626.HK) achieved Q3 net revenue of 7.69 billion yuan (1.08 billion USD), a year-on-year increase of 5%, and turned a profit with a net profit of 469 million yuan (65.9 million USD) [6] Company News - Heng Rui Medicine (01276.HK) received clinical trial approval for its drug, with similar products expected to generate global sales of approximately 11.04 billion USD in 2024 [7] - China Pacific Insurance (02601.HK) reported that for the first ten months, life insurance premium income reached 241.32 billion yuan, a year-on-year increase of 9.9% [8] - Zhong An Online (06060.HK) reported total original insurance premium income of approximately 29.82 billion yuan for the first ten months, a year-on-year increase of 5.18% [9] Buyback Activities - Yongsheng Services (01995.HK) plans to repurchase up to approximately 173 million shares, accounting for about 10% of the issued share capital [12] - Kintor Pharmaceutical (02171.HK) intends to repurchase up to approximately 25.46 million shares [13] - China Feihe (06186.HK) spent 87.86 million HKD to repurchase 20 million shares at prices ranging from 4.37 to 4.40 HKD [14]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Ruvelimab tablets, which will soon commence phase III trials for prostate cancer treatment [1] Group 1: Clinical Trial Approval - The National Medical Products Administration approved the clinical trial application for Ruvelimab tablets on August 26, 2025, allowing the company to conduct phase III clinical trials for prostate cancer [1] - Ruvelimab tablets are classified as a second-generation AR inhibitor, offering stronger AR inhibition without androgenic effects compared to first-generation inhibitors [1] Group 2: Market Context - Ruvelimab tablets were approved for market release in 2022 for treating high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC) patients [1] - Competing second-generation AR inhibitors currently available in the market include Enzalutamide, Apalutamide, and Darolutamide [1] - According to EvaluatePharma, the global sales of similar products are projected to reach approximately $11.037 billion in 2024 [1] Group 3: Research Investment - The total research and development investment for Ruvelimab tablets has reached approximately 693.09 million yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 中國上海 2025年11月13日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-1 ...

Core Insights - The article highlights the top and bottom performing AH share premium rates as of November 12, with Northeast Electric (00042) leading at 847.37% and Ningde Times (03750) at -15.85% [1][2] Summary by Category Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 847.37% with H-share priced at 0.285 HKD and A-share at 2.25 CNY [1] - Hongye Futures (03678) follows with a premium rate of 266.57%, H-share at 3.590 HKD and A-share at 10.99 CNY [1] - Zhejiang Shibao (01057) ranks third with a premium rate of 264.95%, H-share at 4.650 HKD and A-share at 14.17 CNY [1] Bottom AH Share Premium Rates - Ningde Times (03750) shows a negative premium rate of -15.85%, with H-share at 550.000 HKD and A-share at 386.38 CNY [1] - China Merchants Bank (03968) has a premium rate of -1.59%, H-share at 52.250 HKD and A-share at 42.93 CNY [1] - Heng Rui Pharmaceutical (01276) has a premium rate of 3.59%, H-share at 71.800 HKD and A-share at 62.1 CNY [1] Top AH Share Deviation Values - Zhejiang Shibao (01057) leads with a deviation value of 27.23% [1] - Hongye Futures (03678) has a deviation value of 25.25% [1] - Sinopec Oilfield Service (01033) follows with a deviation value of 20.25% [1] Bottom AH Share Deviation Values - Andeli Juice (02218) has the lowest deviation value at -25.93% [1] - China Life (02628) follows with -19.73% [1] - CNOOC Services (02883) has a deviation value of -13.96% [1]

Group 1 - The company, Heng Rui Pharmaceutical (01276.HK), announced a share buyback plan on November 11, 2025, involving an expenditure of RMB 9.1526 million to repurchase 150,000 A shares [1] - The buyback price per share is set between RMB 61.01 and RMB 61.07 [1]

Core Viewpoint - Heng Rui Medicine (01276) announced a share buyback plan, intending to repurchase 150,000 A-shares at a cost of 9.1526 million yuan, scheduled for November 11, 2025 [1] Company Summary - The company is engaging in a share repurchase, which indicates a strategy to enhance shareholder value and potentially signal confidence in its future performance [1] - The total amount allocated for the buyback is 9.1526 million yuan, reflecting the company's commitment to returning capital to shareholders [1]

表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 呈交日期： 2025年11月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總 ...